RSS feed

Publications (original articles or review articles) published in 2024 from OUS - Section for Breast Oncology

11 publications found

Andresen NK, Røssevold AH, Borgen E, Schirmer CB, Gilje B, Garred Ø, Lømo J, Stensland M, Nordgård O, Falk RS, Mathiesen RR, Russnes HG, Kyte JA, Naume B (2024)
Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials
Mol Oncol (in press)
DOI 10.1002/1878-0261.13675, PubMed 38978352

Andresen NK, Røssevold AH, Quaghebeur C, Gilje B, Boge B, Gombos A, Falk RS, Mathiesen RR, Julsrud L, Garred Ø, Russnes HG, Lereim RR, Chauhan SK, Lingjærde OC, Dunn C, Naume B, Kyte JA (2024)
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial
J Immunother Cancer, 12 (1)
DOI 10.1136/jitc-2023-007990, PubMed 38242720

Azim HA, Niman SM, Partridge AH, Demeestere I, Ruggeri M, Colleoni M, Saura C, Shimizu C, Saetersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Ruíz-Borrego M, Moore HCF, Saunders C, Bjelic-Radisic V et al. (2024)
Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy
J Clin Oncol, 42 (23), 2822-2832
DOI 10.1200/JCO.23.02292, PubMed 38810178

Chauhan SK, Dunn C, Andresen NK, Røssevold AH, Skorstad G, Sike A, Gilje B, Raj SX, Huse K, Naume B, Kyte JA (2024)
Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation
NPJ Breast Cancer, 10 (1), 30
DOI 10.1038/s41523-024-00638-2, PubMed 38653982

Egeland EV, Seip K, Skourti E, Øy GF, Pettersen SJ, Pandya AD, Dahle MA, Haugen MH, Kristian A, Nakken S, Engebraaten O, Mælandsmo GM, Prasmickaite L (2024)
The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy
Br J Cancer, 131 (10), 1656-1667
DOI 10.1038/s41416-024-02875-5, PubMed 39390250

Fleischer T, Haugen MH, Ankill J, Silwal-Pandit L, Børresen-Dale AL, Hedenfalk I, Hatschek T, Tost J, Engebraaten O, Kristensen VN (2024)
An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer
Mol Oncol, 18 (8), 2042-2059
DOI 10.1002/1878-0261.13656, PubMed 38671580

Ohnstad HO, Blix ES, Akslen LA, Gilje B, Raj SX, Skjerven H, Borgen E, Janssen EAM, Mortensen E, Brekke MB, Falk RS, Schlichting E, Boge B, Songe-Møller S, Olsson P, Heie A, Mannsåker B, Vestlid MA, Kursetgjerde T, Gravdehaug B, Suhrke P, Sanchez E, Bublevic J, Røe OD, Geitvik GA et al. (2024)
Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1)
ESMO Open, 9 (6), 103475
DOI 10.1016/j.esmoop.2024.103475, PubMed 38838499

Sharma A, Debik J, Naume B, Ohnstad HO, Oslo Breast Cancer Consortium (OSBREAC), Bathen TF, Giskeødegård GF (2024)
Comprehensive multi-omics analysis of breast cancer reveals distinct long-term prognostic subtypes
Oncogenesis, 13 (1), 22
DOI 10.1038/s41389-024-00521-6, PubMed 38871719

Støyten M, Knutsen T, Stikbakke E, Agledahl I, Wilsgaard T, Eggen AE, Richardsen E, Giovannucci E, Thune I, Haugnes HS (2024)
Excess weight, weight gain, and prostate cancer risk and prognosis: the PROCA-life study
Acta Oncol, 63, 154-163
DOI 10.2340/1651-226X.2024.32953, PubMed 38591351

Svendsen K, Leithe S, Trewin-Nybråten CB, Balto A, Nes LS, Meland A, Børøsund E, Kiserud CE, Reinertsen KV, Eriksen HR, Gjelsvik YM, Ursin G (2024)
How Did Breast Cancer Patients Fare during Different Phases of the COVID-19 Pandemic in Norway Compared to Age-Matched Controls?
Cancers (Basel), 16 (3)
DOI 10.3390/cancers16030602, PubMed 38339359

Ullern A, Holm K, Røssevold AH, Andresen NK, Bang C, Lingjærde OC, Naume B, Hov JR, Kyte JA (2024)
Gut microbiota diversity is prognostic and associated with benefit from chemo-immunotherapy in metastatic triple-negative breast cancer
Mol Oncol (in press)
DOI 10.1002/1878-0261.13760, PubMed 39545921